Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | BPTF | Q12830 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653224 | 1.00 | FUCA1 (0.55) | FUCA1SIGMAR1BPTFDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2264027 | 0.98 | FUCA1 (0.53) | FUCA1SIGMAR1BPTFDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3018917 | 0.98 | FUCA1 (0.53) | FUCA1SIGMAR1BPTFDRD2DRD3 | |
| SCHEMBL16344546 | 0.90 | HRH4 (0.49) | FUCA1BPTFS1PR1S1PR5 | |
| SCHEMBL928351 | 0.88 | SIGMAR1 (0.50) | FUCA1SIGMAR1DRD2DRD3GRIN2B | |
| SCHEMBL3784554 | 0.88 | SIGMAR1 (0.50) | FUCA1SIGMAR1DRD2DRD3GRIN2B | |
| SCHEMBL6217555 | 0.88 | ACHE (0.55) | SIGMAR1DRD2DRD3 | |
| SCHEMBL6640228 | 0.88 | ACHE (0.55) | SIGMAR1DRD2DRD3 | |
| SCHEMBL3777655 | 0.88 | SIGMAR1 (0.50) | FUCA1SIGMAR1DRD2DRD3GRIN2B | |
| SCHEMBL3781490 | 0.88 | ACHE (0.55) | SIGMAR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | claimed |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-11 | — | — | US | claimed |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| EP-3600290-B1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120035580-A | Novel piperazinyl sulfonamides and their use as neuroprotective and/or neurorestorative agents | 基因密码公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| EP-0828741-B1 | SPIROCYCLIC AND BICYCLIC DIAZINYL AND CARBAZINYL OXAZOLIDINONES | UPJOHN CO (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000055143-A1 | OXAZOLONE DERIVATIVES AND THEIR USE AS ALPHA-1 ADRENORECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-21 | — | — | WO | disclosed |
| US-6107321-A | Diazabicyclooctane derivatives having selective 5-HT1Dalpha agonist activity | MERCK SHARP & DOHME LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-6090820-A | MICROBIOCIDES, BATERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0828741-A1 | SPIROCYCLIC AND BICYCLIC DIAZINYL AND CARBAZINYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1997011945-A1 | DIAZABICYCLOOCTANE DERIVATIVES HAVING SELECTIVE 5-HT1DALPHA ANTAGONIST ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 1997-04-03 | — | — | WO | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996035691-A1 | SPIROCYCLIC AND BICYCLIC DIAZINYL AND CARBAZINYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | FUCA1 2436/4885SIGMAR1 32/4885BPTF 4272/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | FUCA1 4849/4885SIGMAR1 366/4885BPTF 2673/4885 |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | FUCA1 4849/4885SIGMAR1 366/4885BPTF 2673/4885 |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | FUCA1 1382/4885SIGMAR1 289/4885BPTF 2548/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | FUCA1 4849/4885SIGMAR1 366/4885BPTF 2673/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | FUCA1 1477/4885SIGMAR1 1/4885BPTF 3736/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | FUCA1 4783/4885SIGMAR1 77/4885BPTF 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.